Here's Why Palatin Technologies, Inc. (PTN) Is a Great 'Buy the Bottom' Stock NowZacks Investment Research • 12/06/21
Notice of Allowance Issued for Method of Treating Cytokine Storm Using Melanocortin-Specific PeptidePRNewsWire • 11/30/21
Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 11/15/21
Palatin Reports First Quarter Fiscal Year 2022 Results and Provides Corporate UpdatePRNewsWire • 11/15/21
Palatin to Report First Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on November 15, 2021PRNewsWire • 11/10/21
Palatin Awarded "Top 10 Poster" Designation at the American Society of Retina Specialists (ASRS) 2021 Annual MeetingPRNewsWire • 10/22/21
Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 09/29/21
Palatin Reports Fourth Quarter and Full Year Fiscal Year 2021 Financial Results and Provides Corporate UpdatePRNewsWire • 09/29/21
Palatin Announces Presentation of Positive Protective Effects of PL8331 and PL9654 on Retinal Inflammation at the 2021 American Society of Retina Specialists (ASRS) Annual MeetingPRNewsWire • 09/27/21
Palatin To Report Fourth Quarter And Fiscal Year End 2021 Results; Teleconference And Webcast To Be Held On September 29, 2021PRNewsWire • 09/24/21
Palatin to Participate in H.C. Wainwright 23rd Annual Global Investment Virtual ConferencePRNewsWire • 09/13/21
Palatin Technologies Stock Moves Higher After Outlining Plans For Dry Eye Disease TreatmentBenzinga • 06/29/21
Palatin Announces Positive End-of-Phase 2 Meeting with FDA on PL9643 for the Treatment of Dry Eye DiseasePRNewsWire • 06/29/21
Palatin Technologies' (PTN) CEO Carl Spana on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/17/21